Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
Authors
Keywords
-
Journal
OncoTargets and Therapy
Volume Volume 13, Issue -, Pages 6109-6129
Publisher
Informa UK Limited
Online
2020-06-26
DOI
10.2147/ott.s205950
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients
- (2020) Alessandra Battaglia et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study
- (2020) Molly Brewer et al. GYNECOLOGIC ONCOLOGY
- iRECIST: how to do it
- (2020) Thorsten Persigehl et al. CANCER IMAGING
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Immunotherapy in ovarian cancer: fake news or the real deal?
- (2019) Christian Marth et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
- (2019) Marie Christine Wulff Westergaard et al. BRITISH JOURNAL OF CANCER
- A phase II trial of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
- (2019) E. Zsiros et al. GYNECOLOGIC ONCOLOGY
- Ovarian Cancer Immunotherapy: Turning up the Heat
- (2019) Eleonora Ghisoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced stage ovarian cancer
- (2019) Kristin G. Anderson et al. Cancer Immunology Research
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
- (2019) Alexandra S. Zimmer et al. Journal for ImmunoTherapy of Cancer
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- (2019) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Immunotherapy in Ovarian Cancer: Are We There Yet?
- (2019) Lana E. Kandalaft et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
- (2019) Apostolos Sarivalasis et al. Journal of Translational Medicine
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy
- (2019) Zhaoxu Xu et al. LIFE SCIENCES
- Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
- (2018) Eric Pujade-Lauraine et al. Future Oncology
- Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
- (2018) U.A. Matulonis et al. GYNECOLOGIC ONCOLOGY
- An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2018) Y. Drew et al. GYNECOLOGIC ONCOLOGY
- Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management
- (2018) Katsutoshi Oda et al. GYNECOLOGIC ONCOLOGY
- Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study
- (2018) Magnus Pedersen et al. OncoImmunology
- 979POregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort
- (2018) J J Chan et al. ANNALS OF ONCOLOGY
- 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
- (2018) R E O’Cearbhaill et al. ANNALS OF ONCOLOGY
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy
- (2018) Yun Zhou et al. OncoImmunology
- NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer
- (2017) J. Brian Szender et al. GYNECOLOGIC ONCOLOGY
- A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients
- (2017) Alessandra Battaglia et al. IMMUNOLOGY LETTERS
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Update on immune checkpoint inhibitors in gynecological cancers
- (2017) Valerie Heong et al. Journal of Gynecologic Oncology
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- CAR-T cell therapy in ovarian cancer: from the bench to the bedside
- (2017) Xinxin Zhu et al. Oncotarget
- Immunogenicity of Allo-Vesicle Carrying ERBB2 Tumor Antigen for Dendritic Cell-Based Anti-Tumor Immunotherapy
- (2017) C. Napoletano et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Low dose cyclophosphamide: Mechanisms of T cell modulation
- (2016) Mutsa Tatenda Madondo et al. CANCER TREATMENT REVIEWS
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview
- (2016) Angela K.B. Alme et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial
- (2016) H. J. Gray et al. Journal for ImmunoTherapy of Cancer
- Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy
- (2015) Zhigang Zhang et al. CANCER LETTERS
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
- (2015) Francesca De Felice et al. Journal of Immunology Research
- Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival—a substudy of the MIMOSA trial
- (2014) Alexia Buzzonetti et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Maintenance Therapy With Autologous Cytokine-induced Killer Cells in Patients With Advanced Epithelial Ovarian Cancer After First-line Treatment
- (2014) Jun Liu et al. JOURNAL OF IMMUNOTHERAPY
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
- (2014) Stéphane Champiat et al. Journal of Thoracic Oncology
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
- (2014) Mildred Felder et al. Molecular Cancer
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
- (2014) K. Odunsi et al. Cancer Immunology Research
- Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study
- (2013) Paul Sabbatini et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
- (2013) T. Tsuji et al. Cancer Immunology Research
- Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
- (2012) P. Sabbatini et al. CLINICAL CANCER RESEARCH
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
- (2012) K. Odunsi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
- (2011) D.-G. Song et al. CANCER RESEARCH
- Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
- (2011) Mikayel Mkrtichyan et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen
- (2010) A. A. Chekmasova et al. CLINICAL CANCER RESEARCH
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy
- (2008) Chiara Napoletano et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started